I have theT315I mutationbut also haveelevated lipaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibTreatmentfor blastphaseCMLWhen togive H2RAswithdasatinibThe scoringsystem usedin chronicphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseToo many ofthese bloodcells areabnormal inCMLNumber ofblastspresent inacceleratedphase60-70% ofpatients withCML presentwith thissymptomTKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLTranslocationbetweenthese twochromosomesoccur in CMLNon-pharmacologicaltreatment forCMLThe current5-yearoverallsurvival rateof CMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Responsewhen BCR-ABL1 (IS)is <0.01%I failed 3lines of TKIs,I can try thisagent nextModerateto highemetogenicrisk TKIsThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseThis TKI hasthe mostmetabolicsyndromeDrug classthatrevolutionizedCMLtreatmentI want toavoid thisTKI if I donot wantdiarrheaTherecommendedcriteria usedfor acceleratedphaseI have theT315I mutationbut also haveelevated lipaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibTreatmentfor blastphaseCMLWhen togive H2RAswithdasatinibThe scoringsystem usedin chronicphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseToo many ofthese bloodcells areabnormal inCMLNumber ofblastspresent inacceleratedphase60-70% ofpatients withCML presentwith thissymptomTKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLTranslocationbetweenthese twochromosomesoccur in CMLNon-pharmacologicaltreatment forCMLThe current5-yearoverallsurvival rateof CMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Responsewhen BCR-ABL1 (IS)is <0.01%I failed 3lines of TKIs,I can try thisagent nextModerateto highemetogenicrisk TKIsThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseThis TKI hasthe mostmetabolicsyndromeDrug classthatrevolutionizedCMLtreatmentI want toavoid thisTKI if I donot wantdiarrheaTherecommendedcriteria usedfor acceleratedphase

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
N
2
I
3
I
4
G
5
B
6
I
7
N
8
O
9
G
10
I
11
O
12
G
13
O
14
I
15
B
16
B
17
O
18
G
19
G
20
B
21
O
22
N
23
B
24
N
  1. N-I have the T315I mutation but also have elevated lipase
  2. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  3. I-Treatment for blast phase CML
  4. G-When to give H2RAs with dasatinib
  5. B-The scoring system used in chronic phase
  6. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  7. N-Too many of these blood cells are abnormal in CML
  8. O-Number of blasts present in accelerated phase
  9. G-60-70% of patients with CML present with this symptom
  10. I-TKIs are major substrates for this liver enzyme
  11. O-The number of distinct clinical phases in CML
  12. G-Translocation between these two chromosomes occur in CML
  13. O-Non-pharmacological treatment for CML
  14. I-The current 5-year overall survival rate of CML
  15. B-Patients have presence of this BCR-ABL protein indicative of CML
  16. B-Response when BCR-ABL1 (IS) is <0.01%
  17. O-I failed 3 lines of TKIs, I can try this agent next
  18. G-Moderate to high emetogenic risk TKIs
  19. G-The landmark for the first TKI
  20. B-Percentage of blasts present in the blast phase
  21. O-This TKI has the most metabolic syndrome
  22. N-Drug class that revolutionized CML treatment
  23. B-I want to avoid this TKI if I do not want diarrhea
  24. N-The recommended criteria used for accelerated phase